中华皮肤科杂志 ›› 2024, Vol. 57 ›› Issue (3): 201-208.doi: 10.35541/cjd.20230711
中国医学科学院皮肤病医院 中国疾病预防控制中心性病控制中心 中华医学会皮肤性病学分会性病学组 中国康复医学会皮肤病康复专业委员会
收稿日期:2023-12-04
修回日期:2024-01-08
发布日期:2024-03-04
通讯作者:
苏晓红；王千秋；刘全忠
E-mail:suxh@ncstdlc.org; wangqq@ncstdlc.org; liuquanzhong@tmu.edu.cn
基金资助:Hospital for Skin Diseases, Chinese Academy of Medical Sciences; National Center for STD Control, Chinese Center for Disease Control and Prevention; Venereology Group, Chinese Society of Dermatology; Chinese Association Rehabilitation of Dermatology
Received:2023-12-04
Revised:2024-01-08
Published:2024-03-04
Contact:
Su Xiaohong; Wang Qianqiu; Liu Quanzhong
E-mail:suxh@ncstdlc.org; wangqq@ncstdlc.org; liuquanzhong@tmu.edu.cn
Supported by:摘要： 【摘要】 生殖支原体可引起尿道炎、宫颈炎和盆腔炎等泌尿生殖道感染，并且与早产相关。因培养困难，诊断依赖于核酸检测，其耐药性增加导致临床治疗面临巨大挑战。中国医学科学院皮肤病医院、中国疾病与预防控制中心性病控制中心、中华医学会皮肤性病学分会和中国康复医学会皮肤病康复专业委员会组织国内有关专家依据国际最新生殖支原体诊疗指南及国内外研究进展，围绕生殖支原体感染病原学、流行病学、临床表现、实验室检测、诊断与治疗、随访和判愈、性伴管理、预防等内容进行充分讨论，形成此共识，旨在提高我国临床医师对生殖支原体感染的认识和诊疗水平。
中国医学科学院皮肤病医院 中国疾病预防控制中心性病控制中心 中华医学会皮肤性病学分会性病学组 中国康复医学会皮肤病康复专业委员会. [开放获取] 中国生殖支原体感染诊疗专家共识（2024）[J]. 中华皮肤科杂志, 2024,57(3):201-208. doi:10.35541/cjd.20230711
Hospital for Skin Diseases, Chinese Academy of Medical Sciences, National Center for STD Control, Chinese Center for Disease Control and Prevention, Venereology Group, Chinese Society of Dermatology, Chinese Association Rehabilitation of Dermatology . Chinese expert consensus on the diagnosis and treatment of Mycoplasma genitalium infection （2024）[J]. Chinese Journal of Dermatology, 2024, 57(3): 201-208.doi:10.35541/cjd.20230711
| ［1］ | Taylor⁃Robinson D, Jensen JS. Mycoplasma genitalium: from chrysalis to multicolored butterfly［J］. Clin Microbiol Rev, 2011,24（3）:498⁃514. doi: 10.1128/CMR.00006⁃11. |
| ［2］ | Horner PJ, Martin DH. Mycoplasma genitalium infection in men［J］. J Infect Dis, 2017,216（suppl_2）:S396⁃S405. doi: 10.1093/infdis/jix145. |
| ［3］ | Lis R, Rowhani⁃Rahbar A, Manhart LE. Mycoplasma genitalium infection and female reproductive tract disease: a meta⁃analysis［J］. Clin Infect Dis, 2015,61（3）:418⁃426. doi: 10.1093/cid/civ312. |
| ［4］ | Barker EK, Malekinejad M, Merai R, et al. Risk of human immunodeficiency virus acquisition among high⁃risk hetero⁃sexuals with nonviral sexually transmitted infections: a systematic review and meta⁃analysis［J］. Sex Transm Dis, 2022,49（6）:383⁃397. doi: 10.1097/OLQ.0000000000001601. |
| ［5］ | Manhart LE, Mostad SB, Baeten JM, et al. High Mycoplasma genitalium organism burden is associated with shedding of HIV⁃1 DNA from the cervix［J］. J Infect Dis, 2008,197（5）:733⁃736. doi: 10.1086/526501. |
| ［6］ | US Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States, 2019［EB］. Atlanta: Department of Health and Human Services, 2019. |
| ［7］ | Jensen JS, Cusini M, Gomberg M, et al. 2016 European guideline on Mycoplasma genitalium infections［J］. J Eur Acad Dermatol Venereol, 2016,30（10）:1650⁃1656. doi: 10.1111/jdv.13849. |
| ［8］ | Jensen JS, Cusini M, Gomberg M, et al. 2021 European guideline on the management of Mycoplasma genitalium infections［J］. J Eur Acad Dermatol Venereol, 2022,36（5）:641⁃650. doi: 10. 1111/jdv.17972. |
| ［9］ | 王千秋, 刘全忠, 徐金华, 等. 性传播疾病临床诊疗与防治指南［M］. 2版. 上海: 上海科学技术出版社, 2020. |
| ［10］ | Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations［J］. BMJ, 2008,336（7650）:924⁃926. doi: 10. 1136/bmj.39489.470347.AD. |
| ［11］ | Dehon PM, McGowin CL. The immunopathogenesis of Mycoplasma genitalium infections in women: a narrative review［J］. Sex Transm Dis, 2017,44（7）:428⁃432. doi: 10.1097/OLQ. 0000000000000621. |
| ［12］ | Fraser CM, Gocayne JD, White O, et al. The minimal gene complement of Mycoplasma genitalium［J］. Science, 1995,270（5235）:397⁃403. doi: 10.1126/science.270.5235.397. |
| ［13］ | Burgos R, Pich OQ, Ferrer⁃Navarro M, et al. Mycoplasma genitalium P140 and P110 cytadhesins are reciprocally stabilized and required for cell adhesion and terminal⁃organelle development［J］. J Bacteriol, 2006,188（24）:8627⁃8637. doi: 10. 1128/JB.00978⁃06. |
| ［14］ | Li L, Krishnan M, Baseman JB, et al. Molecular cloning, expression, and characterization of a Ca2+⁃dependent, membrane⁃associated nuclease of Mycoplasma genitalium［J］. J Bacteriol, 2010,192（19）:4876⁃4884. doi: 10.1128/JB.00401⁃10. |
| ［15］ | Christodoulides A, Gupta N, Yacoubian V, et al. The role of lipoproteins in Mycoplasma⁃mediated immunomodulation［J］. Front Microbiol, 2018,9:1682. doi: 10.3389/fmicb.2018.01682. |
| ［16］ | Burgos R, Wood GE, Iverson⁃Cabral SL, et al. Mycoplasma genitalium nonadherent phase variants arise by multiple mechanisms and escape antibody⁃dependent growth inhibition［J］. Infect Immun, 2018,86（4）. doi: 10.1128/IAI.00866⁃17. |
| ［17］ | Arfi Y, Minder L, Di Primo C, et al. MIB⁃MIP is a mycoplasma system that captures and cleaves immunoglobulin G［J］. Proc Natl Acad Sci U S A, 2016,113（19）:5406⁃5411. doi: 10.1073/pnas.1600546113. |
| ［18］ | McAuliffe L, Ellis RJ, Miles K, et al. Biofilm formation by mycoplasma species and its role in environmental persistence and survival［J］. Microbiology （Reading）, 2006,152（Pt 4）:913⁃922. doi: 10.1099/mic.0.28604⁃0. |
| ［19］ | Li Y, Su X, Le W, et al. Mycoplasma genitalium in symptomatic male urethritis: macrolide use is associated with increased resistance［J］. Clin Infect Dis, 2020,70（5）:805⁃810. doi: 10. 1093/cid/ciz294. |
| ［20］ | Shipitsyna E, Kularatne R, Golparian D, et al. Mycoplasma genitalium prevalence, antimicrobial resistance⁃associated mutations, and coinfections with non⁃viral sexually transmitted infections in high⁃risk populations in Guatemala, Malta, Morocco, Peru and South Africa, 2019 -2021［J］. Front Microbiol, 2023,14:1130762. doi: 10.3389/fmicb.2023.1130762. |
| ［21］ | Aboud S, Buhalata SN, Onduru OG, et al. High prevalence of Sexually Transmitted and Reproductive Tract Infections （STI/RTIs） among patients attending STI/Outpatient department clinics in Tanzania［J］. Trop Med Infect Dis, 2023,8（1）. doi: 10.3390/tropicalmed8010062. |
| ［22］ | Baumann L, Cina M, Egli⁃Gany D, et al. Prevalence of Mycoplasma genitalium in different population groups: systematic review and meta⁃analysis［J］. Sex Transm Infect, 2018,94（4）:255⁃262. doi: 10.1136/sextrans⁃2017⁃053384. |
| ［23］ | 宣岩, 魏兰馨, 洪翔, 等. 我国不同人群生殖支原体感染率的Meta分析［J］. 中华流行病学杂志, 2021,42（2）:335⁃342. doi: 10.3760/cma.j.cn112338⁃20200530⁃00791. |
| ［24］ | Cina M, Baumann L, Egli⁃Gany D, et al. Mycoplasma genitalium incidence, persistence, concordance between partners and progression: systematic review and meta⁃analysis［J］. Sex Transm Infect, 2019,95（5）:328⁃335. doi: 10.1136/sextrans⁃2018⁃053823. |
| ［25］ | Balkus JE, Manhart LE, Jensen JS, et al. Mycoplasma genitalium infection in Kenyan and US Women［J］. Sex Transm Dis, 2018,45（8）:514⁃521. doi: 10.1097/OLQ.0000000000000799. |
| ［26］ | Latimer RL, Vodstrcil L, De Petra V, et al. Extragenital Mycoplasma genitalium infections among men who have sex with men［J］. Sex Transm Infect, 2020,96（1）:10⁃18. doi: 10.1136/sextrans⁃2019⁃054058. |
| ［27］ | Sonnenberg P, Ison CA, Clifton S, et al. Epidemiology of Mycoplasma genitalium in British men and women aged 16 - 44 years: evidence from the third National Survey of Sexual Attitudes and Lifestyles （Natsal⁃3）［J］. Int J Epidemiol, 2015,44（6）:1982⁃1994. doi: 10.1093/ije/dyv194. |
| ［28］ | Bissessor M, Tabrizi SN, Bradshaw CS, et al. The contribution of Mycoplasma genitalium to the aetiology of sexually acquired infectious proctitis in men who have sex with men［J］. Clin Microbiol Infect, 2016,22（3）:260⁃265. doi: 10.1016/j.cmi.2015. 11.016. |
| ［29］ | Francis SC, Kent CK, Klausner JD, et al. Prevalence of rectal Trichomonas vaginalis and Mycoplasma genitalium in male patients at the San Francisco STD clinic, 2005 -2006［J］. Sex Transm Dis, 2008,35（9）:797⁃800. doi: 10.1097/OLQ.0b013e 318177ec39. |
| ［30］ | Ong JJ, Aung E, Read T, et al. Clinical characteristics of anorectal Mycoplasma genitalium infection and microbial cure in men who have sex with men［J］. Sex Transm Dis, 2018,45（8）:522⁃526. doi: 10.1097/OLQ.0000000000000793. |
| ［31］ | Ito S, Tsuchiya T, Yasuda M, et al. Prevalence of genital mycoplasmas and ureaplasmas in men younger than 40 years⁃of⁃age with acute epididymitis［J］. Int J Urol, 2012,19（3）:234⁃238. doi: 10.1111/j.1442⁃2042.2011.02917.x. |
| ［32］ | Krieger JN, Riley DE, Roberts MC, et al. Prokaryotic DNA sequences in patients with chronic idiopathic prostatitis［J］. J Clin Microbiol, 1996,34（12）:3120⁃3128. doi: 10.1128/jcm.34.12. 3120⁃3128.1996. |
| ［33］ | Mo X, Zhu C, Gan J, et al. Prevalence and correlates of Mycoplasma genitalium infection among prostatitis patients in Shanghai, China［J］. Sex Health, 2016,doi: 10.1071/SH15155. |
| ［34］ | Ahmadi MH, Mirsalehian A, Gilani M, et al. Improvement of semen parameters after antibiotic therapy in asymptomatic infertile men infected with Mycoplasma genitalium［J］. Infection, 2018,46（1）:31⁃38. doi: 10.1007/s15010⁃017⁃1075⁃3. |
| ［35］ | Huang C, Zhu HL, Xu KR, et al. Mycoplasma and ureaplasma infection and male infertility: a systematic review and meta⁃analysis［J］. Andrology, 2015,3（5）:809⁃816. doi: 10.1111/andr. 12078. |
| ［36］ | Olson E, Gupta K, Van Der Pol B, et al. Mycoplasma genitalium infection in women reporting dysuria: a pilot study and review of the literature［J］. Int J STD AIDS, 2021,32（13）:1196⁃1203. doi: 10.1177/09564624211030040. |
| ［37］ | Lewis J, Horner PJ, White PJ. Incidence of pelvic inflammatory disease associated with Mycoplasma genitalium infection: evidence synthesis of cohort study data［J］. Clin Infect Dis, 2020,71（10）:2719⁃2722. doi: 10.1093/cid/ciaa419. |
| ［38］ | Latimer RL, Read T, Vodstrcil LA, et al. Clinical features and therapeutic response in women meeting criteria for presumptive treatment for pelvic inflammatory disease associated with Mycoplasma genitalium［J］. Sex Transm Dis, 2019,46（2）:73⁃79. doi: 10.1097/OLQ.0000000000000924. |
| ［39］ | Frenzer C, Egli⁃Gany D, Vallely LM, et al. Adverse pregnancy and perinatal outcomes associated with Mycoplasma genitalium: systematic review and meta⁃analysis［J］. Sex Transm Infect, 2022,98（3）:222⁃227. doi: 10.1136/sextrans⁃2021⁃055352. |
| ［40］ | Workowski KA, Bachmann LH, Chan PA, et al. Sexually transmitted infections treatment guidelines, 2021［J］. MMWR Recomm Rep, 2021,70（4）:1⁃187. doi: 10.15585/mmwr.rr7004a1. |
| ［41］ | The Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine （ASHM）. Australian STI management guidelines for use in primary care［EB/OL］. ［2023⁃07⁃20］. https://sti.guidelines.org.au/sexually⁃transmissible⁃infections/mycoplasma⁃genitalium/. |
| ［42］ | Soni S, Horner P, Rayment M, et al. British Association for Sexual Health and HIV national guideline for the management of infection with Mycoplasma genitalium （2018）［J］. Int J STD AIDS, 2019,30（10）:938⁃950. doi: 10.1177/0956462419825948. |
| ［43］ | Jensen JS, Björnelius E, Dohn B, et al. Comparison of first void urine and urogenital swab specimens for detection of Mycoplasma genitalium and Chlamydia trachomatis by polymerase chain reaction in patients attending a sexually transmitted disease clinic［J］. Sex Transm Dis, 2004,31（8）:499⁃507. doi: 10.1097/01.olq.0000135992.98883.e4. |
| ［44］ | Gaydos CA, Manhart LE, Taylor SN, et al. Molecular testing for Mycoplasma genitalium in the United States: results from the AMES prospective multicenter clinical study［J］. J Clin Microbiol, 2019,57（11）:e01125⁃01119. doi: 10.1128/JCM.01125⁃19. |
| ［45］ | Peris MP, Dehesa B, Alonso H, et al. Retrospective and comparative study of three molecular assays for the macrolide resistance detection in Mycoplasma genitalium positive urogenital specimens［J］. Int J Mol Sci, 2023,24（8）:7218. doi: 10.3390/ijms24087218. |
| ［46］ | Fernández⁃Huerta M, Bodiyabadu K, Esperalba J, et al. Multicenter clinical evaluation of a novel multiplex real⁃time PCR （qPCR） assay for detection of fluoroquinolone resistance in Mycoplasma genitalium［J］. J Clin Microbiol, 2019,57（11）:e00886⁃19. doi: 10.1128/JCM.00886⁃19. |
| ［47］ | Bradshaw CS, Jensen JS, Waites KB. New horizons in Mycoplasma genitalium treatment［J］. J Infect Dis, 2017,216（suppl_2）:S412⁃S419. doi: 10.1093/infdis/jix132. |
| ［48］ | Abavisani M, Keikha M. Global analysis on the mutations associated with multidrug⁃resistant urogenital mycoplasmas and ureaplasmas infection: a systematic review and meta⁃analysis［J］. Ann Clin Microbiol Antimicrob, 2023,22（1）:70. doi: 10. 1186/s12941⁃023⁃00627⁃6. |
| ［49］ | Ke W, Li D, Tso LS, et al. Macrolide and fluoroquinolone associated mutations in Mycoplasma genitalium in a retrospective study of male and female patients seeking care at a STI Clinic in Guangzhou, China, 2016 -2018［J］. BMC Infect Dis, 2020,20（1）:950. doi: 10.1186/s12879⁃020⁃05659⁃3. |
| ［50］ | Wang L, Li Z, Wan C, et al. Prevalence of Mycoplasma genitalium infection with antimicrobial resistance mutations among gay sex workers in China［J］. Int J STD AIDS, 2023,34（8）:518⁃524. doi: 10.1177/09564624231160676. |
| ［51］ | Bissessor M, Tabrizi SN, Twin J, et al. Macrolide resistance and azithromycin failure in a Mycoplasma genitalium⁃infected cohort and response of azithromycin failures to alternative antibiotic regimens［J］. Clin Infect Dis, 2015,60（8）:1228⁃1236. doi: 10.1093/cid/ciu1162. |
| ［52］ | Murray GL, Bodiyabadu K, Vodstrcil LA, et al. parC Variants in Mycoplasma genitalium: trends over time and association with moxifloxacin failure［J］. Antimicrob Agents Chemother, 2022,66（5）:e0027822. doi: 10.1128/aac.00278⁃22. |
| ［53］ | Murray GL, Bodiyabadu K, Danielewski J, et al. Moxifloxacin and sitafloxacin treatment failure in Mycoplasma genitalium infection: association with parC mutation G248T （S83I） and concurrent gyrA mutations［J］. J Infect Dis, 2020,221（6）:1017⁃1024. doi: 10.1093/infdis/jiz550. |
| ［54］ | 袁梦瑾. MG感染耐药性和治疗的研究［D］. 北京: 北京协和医学院, 2023. |
| ［55］ | Read T, Fairley CK, Murray GL, et al. Outcomes of resistance⁃guided sequential treatment of Mycoplasma genitalium infections: a prospective evaluation［J］. Clin Infect Dis, 2019,68（4）:554⁃560. doi: 10.1093/cid/ciy477. |
| ［56］ | Durukan D, Read T, Murray G, et al. Resistance⁃guided antimicrobial therapy using doxycycline⁃moxifloxacin and doxycycline⁃2.5 g azithromycin for the treatment of Mycoplasma genitalium infection: efficacy and tolerability［J］. Clin Infect Dis, 2020,71（6）:1461⁃1468. doi: 10.1093/cid/ciz1031. |
| ［57］ | Durukan D, Doyle M, Murray G, et al. Doxycycline and sitafloxacin combination therapy for treating highly resistant Mycoplasma genitalium［J］. Emerg Infect Dis, 2020,26（8）:1870⁃1874. doi: 10.3201/eid2608.191806. |
| ［58］ | 李赛, 薛华忠, 张树文, 等. 多西环素⁃莫西沙星序贯疗法治疗生殖支原体尿道炎/宫颈炎的临床观察［J］. 中华皮肤科杂志, 2022,55（12）:1092⁃1095. doi: 10.35541/cjd.20210631. |
| ［59］ | Li L, Yuan Y, He W, et al. Emerging multidrug resistance contributes to treatment failure in Mycoplasma genitalium infected patients in China［J］. Diagn Microbiol Infect Dis, 2023,105（2）:115854. doi: 10.1016/j.diagmicrobio.2022.115854. |
| ［60］ | Ando N, Mizushima D, Takano M, et al. Effectiveness of sitafloxacin monotherapy for quinolone⁃resistant rectal and urogenital Mycoplasma genitalium infections: a prospective cohort study［J］. J Antimicrob Chemother, 2023,78（8）:2070⁃2079. doi: 10.1093/jac/dkad208. |
| ［61］ | Doyle M, Vodstrcil LA, Plummer EL, et al. Nonquinolone options for the treatment of Mycoplasma genitalium in the era of increased resistance［J］. Open Forum Infect Dis, 2020,7（8）:ofaa291. doi: 10.1093/ofid/ofaa291. |
| ［62］ | Clarke EJ, Vodstrcil LA, Plummer EL, et al. Efficacy of minocycline for the treatment of Mycoplasma genitalium［J］. Open Forum Infect Dis, 2023,10（8）:ofad427. doi: 10.1093/ofid/ofad427. |
| ［63］ | Glaser AM, Geisler WM, Ratliff AE, et al. Two cases of multidrug⁃resistant genitourinary Mycoplasma genitalium infection successfully eradicated with minocycline［J］. Int J STD AIDS, 2019,30（5）:512⁃514. doi: 10.1177/0956462418816757. |
| ［64］ | Read T, Jensen JS, Fairley CK, et al. Use of pristinamycin for macrolide⁃resistant Mycoplasma genitalium infection［J］. Emerg Infect Dis, 2018,24（2）:328⁃335. doi: 10.3201/eid2402.170902. |
| ［65］ | Falk L, Enger M, Jensen JS. Time to eradication of Mycoplasma genitalium after antibiotic treatment in men and women［J］. J Antimicrob Chemother, 2015,70（11）:3134⁃3140. doi: 10.1093/jac/dkv246. |
| [1] | 谢媛媛 刘宇甄 曾荣. 皮肤影像技术在寻常痤疮诊疗中的应用进展[J]. 中华皮肤科杂志, 2024, 57(8): 757-760. |
| [2] | 窦进法 王建波 张帅 李建国 刘鸿伟 张守民. 新型冠状病毒感染疫情期间接受生物制剂治疗的中重度斑块状银屑病患者病情变化及影响因素分析：单中心横断面研究[J]. 中华皮肤科杂志, 2024, 57(8): 739-742. |
| [3] | 任伟琦 邹雅茹 潘敏. 大疱性类天疱疮患者继发感染危险因素的研究进展[J]. 中华皮肤科杂志, 2024, 57(8): 770-772. |
| [4] | 夏曼琪 邵蕾 黄琼霄 田歆 梁毅敏 黄婷 梁景耀 刘玉梅. 度普利尤单抗治疗结节性痒疹疗效与安全性的多中心回顾性分析[J]. 中华皮肤科杂志, 2024, 57(8): 679-684. |
| [5] | 罗莉 张博娜 吴畏 汤文静 李岳华 刘晓莉 马雅楠 李翠翠 齐梦岩 孙妮 石琼. [开放获取] 308 nm准分子激光与308 nm准分子光治疗194例儿童白癜风的疗效及安全性回顾分析[J]. 中华皮肤科杂志, 2024, 57(8): 721-727. |
| [6] | 宋雨晴 杨楠 刘琳琳 冯子仪 韩世新 周梅娟. [开放获取] 皮肤磨削术治疗家族性良性慢性天疱疮6例临床观察[J]. 中华皮肤科杂志, 2024, 57(8): 743-746. |
| [7] | 刘青锋 刘莲 刁萍 李晓雪 张婷 陈浩天 刘绪 蒋献. 鲜红斑痣相关综合征的诊疗进展[J]. 中华皮肤科杂志, 2024, 57(7): 656-660. |
| [8] | 陈浩天 刘莲 张婷 刘青锋 李晓雪 刁萍 蒋献. 鲜红斑痣发病及进展机制研究进展[J]. 中华皮肤科杂志, 2024, 57(7): 661-664. |
| [9] | 刁萍 韩成龙 刘莲 周慧 李二龙 蒋献. 海姆泊芬光动力治疗成人鲜红斑痣的疗效及其影响因素分析：一项回顾性研究[J]. 中华皮肤科杂志, 2024, 57(7): 595-600. |
| [10] | 张婷 刘莲 陈浩天 魏丹凤 刘绪 刁萍 刘青锋 蒋献. 595 nm脉冲染料激光治疗155例婴幼儿鲜红斑痣疗效回顾性分析[J]. 中华皮肤科杂志, 2024, 57(7): 610-615. |
| [11] | 海姆泊芬光动力疗法治疗鲜红斑痣共识制订专家组. [开放获取] 海姆泊芬光动力疗法治疗鲜红斑痣专家共识（2024）[J]. 中华皮肤科杂志, 2024, 57(7): 581-589. |
| [12] | 王晨 薛晨红 宋静卉 李建国 李振鲁 张守民 李明 王建波. 阿达木单抗治疗Blau综合征1家系3例[J]. 中华皮肤科杂志, 2024, 57(6): 553-556. |
| [13] | 隋长霖 常晓 赵琪 朱威. 抗肿瘤靶向和免疫治疗致银屑病研究进展[J]. 中华皮肤科杂志, 2024, 57(6): 570-574. |
| [14] | 王林霞 张立明 史美慧 高兴华 陈洪铎 肖汀. 慢性自发性荨麻疹伴与不伴血管性水肿患者131例临床特征回顾分析[J]. 中华皮肤科杂志, 2024, 57(6): 510-515. |
| [15] | 中华医学会医学美学与美容学分会激光美容学组 中国医学装备协会皮肤病与皮肤美容分会护肤品和护肤材料学组 中国医师协会整形与美容分会激光美容学组 中华医学会皮肤性病学分会美容激光学组 . [开放获取] 化妆品皮肤不良反应诊疗指南（2024版）[J]. 中华皮肤科杂志, 2024, 57(6): 485-492. |
|
